Cispalatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 19, Issue 1, 2000, Pages 13-16

  Massacesi, C ^a   Bascioni, R ^a   Cellerino, R ^a   Scartozzi, M ^a   Bracci, R ^a   Alessandroni, P ^a   Antognoli, S ^a   Ciavattini, A ^a   De Nictolis, M ^a   Piga, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Advanced ovarian cancer; Anthracyclines; Chemotherapy; Cisplatin; Delivered dose intensity

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0033625371     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br. J. Cancer 78: 1479-1487, 1998.
2. McGuire W.P., Hoskins W.J., Brady M.F., et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334: 1-6, 1996.
3. Stuart G., Bertelsen K., Mangioni C., et al.: Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-placlitaxel as first-line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish intergroup trial. Proc. Am. Soc. Clin. Oncol. 17: 1394, 1998 (abstract).
4. A'Hern R.P., Gore M.E.: Impact of doxorubicin on survival in advanced ovarian cancer. J. Clin. Oncol. 13: 726-732, 1995.
5. Miller A.B., Hoogstraten B., Staquet M., Winkler A.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
6. National Cancer Institute guidelines for reporting adverse drug reactions. Bethesda MD, Division of cancer treatment, NCI 1988.
7. The ICON Collaborators: ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 352: 1571-1576, 1998.
8. Conte P.D., Bruzzone M., Chiara S., et al.: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J. Clin. Oncol. 4: 965-971, 1986.
9. Bertelsen K., Jakobsen A., Andersen J.E., et al.: A randomized study of cyclophosphamide and cisplatinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol. Oncol. 28: 161-169, 1987.
10. Hernadi Z., Juhashz B., Poka R., Lampe L.: Randomized trial comparing combination of cyclophosphamide and cisplatin without or with doxorubicin or 4 epi-doxorubicin in the treatment of advanced ovarian cancer. Int. J. Gynecol. Obstet. 27: 199-207, 1988.
11. Omura G.A., Bundy B.N., Berek J.S., Curry S., Delgado G., Mortel R.: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 7: 457-465, 1989.
12. GICOG, Italy: Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol. Oncol. 45: 115-117, 1992.
13. Trimble E.L., Adams J.D., Vena D., et al.: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11: 2405-2410, 1993.
14. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J.: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12: 1748-1753, 1994.
15. ten Bokkel Huinink W., Gore M., Carmchael J., et al.: Topotecan versus paclitaxel for the treatment of recurrent ephitelial ovarian cancer. J. Clin. Oncol. 15: 2183-2193, 1997.
16. Lund B., Hansen O.P., Theilade K.., Hansen M., Neijt J.P.: Phase II study of gemcitabine (2′-difluorodeoxycitidine) in previously treated ovarian cancer patients. J. Natl. Cancer. Inst. 86: 1530-1533, 1994.
17. Muggia F.M., Hainsworth J.D., Jeffers S., et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15: 987-993, 1997.
18. Repetto L., Pace M., Mammoliti S., et al.: The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur. J. Cancer 29A: 181-184, 1993.
19. McGuire W.P., Hoskins W.J., Brady M.F., et al.: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13: 1589-1599, 1995.
20. Conte P.F., Bruzzone M., Carino F., et al.: High dose versus low dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J. Clin. Oncol. 14: 351-356, 1996.
21. Levin L., Hryniuk W.M.: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 5: 756-767, 1987.